Entries by Maren Kühr

A “Pure Play” Biologics Swiss-based CDMO

The biologics contract development and manufacturing (CDMO) market is experiencing rapid growth and is dominated by global players with investments in large scale stainless steel capacity.
But is larger always better? Not necessarily says Celonic, a mid-sized, privately owned CDMO, who has been embracing next generation technologies to help small to large biotech customers bring their drugs reliably, effectively and efficiently to the market.

The West’s wake-up call to China’s biotech dominance

The U.S. House of Representatives recently passed the BIOSECURE Act, prohibiting U.S. biopharma companies from working with Chinese contractors due to national security concerns, including data leaks and intellectual property theft. The Act is expected to pass the Senate.

Experienced CEO appointed

Lori A. Ball has been appointed as the new Chief Executive Officer of UK-based Astoriom. She will be responsible for driving the development of Astoriom’s sample management business in the US, UK and Europe.

Where has the conviction gone?

2023 was another particularly tumultuous year for life sciences and, although the lingering effects of the last year are unlikely to change dramatically, the stabilisation of interest rates (off 16-year highs) and emerging direction of travel (market data points) tilt our bias to positive for the new year.